       Document 0819
 DOCN  M9460819
 TI    Association between ATL and non-hematopoietic neoplasms.
 DT    9404
 AU    Imamura N; Inada T; Tagaya Y; Yodoi J; Kuramoto A; Department of
       Internal Medicine, Hiroshima University, Japan.
 SO    Hematol Oncol. 1993 May-Jun;11(3):127-37. Unique Identifier : AIDSLINE
       MED/94156330
 AB    A high incidence of multiple primary neoplasms has been observed in our
       patients with ATL in comparison to persons with other forms of
       hematologic malignancy who we have observed during the past 23 years
       (1963-1985). Five of 15 patients with ATL (33.3 per cent) have had at
       least one other associated neoplasm in comparison to only 44 of 1156
       patients with other forms of hematological malignancy (3.8 per cent).
       The incidence figures for secondary neoplasms associated with the other
       hematologic malignancies were 4.3 per cent (16/370) for acute
       non-lymphocytic leukemia (ANLL), 2.2 per cent (2/90) for acute
       lymphocytic leukemia (ALL), 4.8 per cent (1/21) for acute unclassifiable
       leukemia, 2.2 per cent (5/225) for chronic myelogenous leukemia, 4.7 per
       cent (2/43) for chronic lymphocytic leukemia, 5.9 per cent (8/136) for
       malignant monoclonal gammopathy and 3.7 per cent (10/271) for malignant
       lymphoma. The incidence of multiple neoplasms in patients with ATL in
       comparison to those with other hematological malignancies was
       statistically significant (p < 0.01 or p < 0.001). The neoplasms
       associated with ATL have been adenocarcinoma of the thyroid or stomach,
       and squamous cell carcinoma of the larynx, lip or lung. We identified
       ATL-derived factor (ADF) in the cytoplasm of the secondary neoplasms of
       the ATL patients by means of indirect immunofluoroscopy and
       immunohistochemical techniques utilizing anti-ADF antibody. We also
       identified ras p21 products in these neoplasms by means of p21 ras
       monoclonal antibody studies. The possibility that HTLV-I was the cause
       of the secondary neoplasms thus was investigated. HTLV-I provirus genome
       was not found in all the six cases of non-ATL leukemic cells of the
       patients with anti-HTLV-I antibodies as determined by means of Southern
       blot analysis utilizing pX DNA probe. These findings suggest that there
       is some association between ATL cells and pre-malignant cells through
       ADF or other unknown factors in the activation of ras oncogenes.
       Subsequent suppression of host immune defence mechanisms in ATL patients
       permits evolution of the secondary neoplasms.
 DE    Adenocarcinoma/PATHOLOGY/ULTRASTRUCTURE  Aged  Carcinoma, Squamous
       Cell/PATHOLOGY/ULTRASTRUCTURE  Head and Neck
       Neoplasms/PATHOLOGY/ULTRASTRUCTURE  Human  HTLV-I/GENETICS/IMMUNOLOGY
       Leukemia, T-Cell/*PATHOLOGY  Male  Middle Age  Neoplasm
       Proteins/ANALYSIS  Neoplasms, Multiple Primary/*PATHOLOGY/ULTRASTRUCTURE
       Proto-Oncogene Protein p21(ras)/ANALYSIS  Thoracic
       Neoplasms/PATHOLOGY/ULTRASTRUCTURE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

